Yohimbine improves lipid and carbohydrate profiles without reduction in body weight in obese leptin-deficient ob/ob mice
More details
Hide details
Department of Pharmacodynamics, Jagiellonian University Collegium Medicum, 9 Medyczna Street, PL 30-688 Kraków, Poland
Department of Medicinal Chemistry, Jagiellonian University Collegium Medicum, 9 Medyczna Street, PL 30-688 Kraków, Poland
Department of Pharmacological Screening, Jagiellonian University Collegium Medicum, 9 Medyczna Street, PL 30-688 Kraków, Poland
Corresponding author
Magdalena Kotańska   

Department of Pharmacodynamics, Jagiellonian University Collegium Medicum, 9 Medyczna Street, PL 30-688 Kraków, Poland, Medyczna 9, 30-688 Krakow, Poland
J Pre Clin Clin Res. 2018;12(2):67-71
Obesity, hyperglycaemia, hyperlipidemia and hypertension are the hallmarks of metabolic syndrome. The epidemic of obesity has been accompanied by an analogous rise in the number of patients with metabolic syndrome. Thus, obesity and related metabolic disturbances are the main objective of public health throughout the world. Previously, we have shown that yohimbine, a non-selective α2-adrenergic receptor antagonist, reduces body weight and improves disrupted lipid and carbohydrates profiles in rats with diet-induced obesity.

Material and methods:
In the presented study we have determined the effect of yohimbine on the body weight and carbohydrate and lipids levels in genetically obese leptin-deficient ob/ob mice and in lean C57BL6 mice.

Yohimbine had a favourable effect on elevated levels of triglycerides, cholesterol and glucose. However, it did not have any influence on body weight.

The obtained data show that the weight reducing activity of yohimbine is primarily mediated via the interaction with α2-adrenergic receptor, and the subsequent enhanced release of noradrenaline which stimulates the β3-adrenergic receptor presented on adipocytes. The favourable influence of yohimbie on impaired lipid-carbohydrate homeostasis is achieved via the blockade of α1-adrenergic receptor. We believe that non-selective α-adrenoceptor antagonists might offer therapeutic benefits in the treatment of obesity and metabolic disturbances.

World Health Organization Obesity and Overweight: World Health Organization global strategy on diet, physical activity and health fact sheet. [Accessed September 16, 2005]. 2003.
Wyatt SB, Winters KP, Dubbert PM (2006) Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 331(4): 166-74.
Ginsberg HN, MacCallum PR (2009) The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: Part I. Increased Cardiovascular Disease Risk and the Importance of Atherogenic Dyslipidemia in Persons With the Metabolic Syndrome and Type Diabetes Mellitus. J Cardiometab Syndr 4(2): 113-119.
Gogga P, Karbowska J, Meissner W, Kochan Z (2011) Role of leptin in the regulation of lipid and carbohydrate metabolism. Postepy Hig. Med. Dosw. (online) 65: 255-262.
Kennedy AJ, Ellacott KLJ, King VL, Hasty AH (2010) Mouse models of the metabolic syndrome. Dis Model Mech 3(3-4): 156-166.
Ohyama T, Sato K, Yamazaki Y, Hashizume H, Horiguchi N, Kakizaki S, Mori M, Kusano M, Yamada M (2014) MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice. World J Gastroenterol 20: 16227-35.
Janhunen SK, van der Zwaal EM, la Fleur SE, Adan RAH (2011) Inverse agonism at α2A adrenoreceptors augments the hypophagic effect of sibutramine in rats. Obesity 19: 1979 1986.
Mukherjee R, Yun JW (2013) Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on α2-adrenergic receptor in 3T3-L1 adipocyte cells. Mol Biol Rep 40: 3783 3792.
Janhunen SK, la Fleur SE, Adan RA (2013) Blocking alpha2A adrenoreceptors, but not dopamine receptors, augments bupropion-induced hypophagia in rats. Obesity 21: 700-8.
Philipp M, Brede M, Hein L (2002) Physiological significance of α2-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 283: 287-295.
Dudek M, Knutelska J, Bednarski M, Nowiński L, Zygmunt M, Mordyl B, Głuch-Lutwin M, Kazek G, Sapa J, Pytka K (2015) The comparison of the anorectic effect and safety of alpha2-adrenoceptor ligands: guanfacine and yohimbine in rats with diet-induced obesity. PlosOne DOI:10.1371/journal.pone.0141327.
dos Santos Moreira MC, de Jesej Pinto IS, Fajemiroye JO, Colombari E, da Silva Reis AA, Freiria-Oliveira AH, Ferreira-Neto ML, Pedrino GR. Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome? (2015) Front Physiol 6: 234.
Beille PE (2013) Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe) EFSA J 11(7): 3302.
Ades PA, Savage PD, Toth MJ, Schneider DJ, Audelin MC, Bunn JY, Ludlow M (2008) The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease. Int J Obes 32: 967–974.
Boundy VA, Cincotta AH (2000) Hypothalamic adrenergic receptor changes in the metabolic syndrome of genetically obese (ob/ob) mice. Am J Physiol Regul Integr Comp Physiol 279(2): R505-514.
Evans BA, Papaioannou M, Anastasopoulos F, Summers RJ (1998) Differential regulation of β3-adrenoceptors in gut and adipose tissue of genetically obese (ob/ob) C57BL/6J-mice. Br J Pharmacol 124: 763 – 771.
Lafontan M, Berlan M (1993) Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 34: 1057-1091.
Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S (1984) Atypical β-adrenoceptors on brown adipocytes as target for anti-obesity drugs. Nature 309: 163-165.
Flechtner-Mors M, Jenkinson CP, Alt A, Biesalski HK, Adler G, Ditschneit HH (2004) Sympathetic Regulation of Glucose Uptake by the α1-Adrenoceptor in Human Obesity. Obesity 12(4): 612-620.
Schlaich M, Straznicky N, Lambert E, Lambert G (2015) Metabolic syndrome: a sympathetic disease? Lancet Diabetes Endocrinol 3(2): 148-157.
Journals System - logo
Scroll to top